Skip to main content

Table 3 Change of secondary outcomes in participants

From: Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus

Term

Type

Baseline

12 weeks

24 weeks

FBG (mg/dL)

1

160.8 ± 68.7

150.2 ± 37.4

149.4 ± 46.7

2

152.9 ± 61.5

141.1 ± 50.0

142.1 ± 51.5

1.5-AG (μg/mL)

1

6.9 ± 5.5

7.8 ± 6.5

9.7 ± 8.8

2

8.0 ± 4.9

10.4 ± 7.2

10.4 ± 5.5

Bolus insulin (IU/day)

1

20.3 ± 6.5

19.4 ± 7.1

19.0 ± 7.3

2

19.9 ± 5.7

20.1 ± 5.5

20.0 ± 5.6

Basal insulin (IU/day)

1

14.4 ± 5.1

12.3 ± 5.0 *

12.3 ± 6.1 *

2

13.4 ± 7.6

11.9 ± 6.7 *

11.4 ± 6.3 *

Body weight (kg)

1

58.7 ± 11.4

57.9 ± 10.8

57.5 ± 11.1

2

66.6 ± 14.7

66.8 ± 14.7

66.9 ± 14.6

  1. Data are mean ± SD. Comparisons were made by ANOVA. * p < 0.05, significantly different from baseline